Hansen Medical Announces First Quarter 2012 Results Conference Call
26 4월 2012 - 5:01AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible
catheter robotics and the developer of robotic technology for
accurate 3D control of catheter movement, today announced that it
will release its financial and operating results for the first
quarter ended March 31, 2012 after market close on Wednesday, May
2, 2012.
Bruce Barclay, President and Chief Executive Officer, will host
a conference call at 5:00 p.m. ET (2:00 p.m. PT) on May 2, 2012 to
discuss the company's results. The call may be accessed by dialing
877-941-8416 (480-629-9808 for international callers) and via the
Internet in the Investor Relations section of Hansen Medical's
website at www.hansenmedical.com. Please go to the website at least
15 minutes early to register, download and install any necessary
audio software. Following the call, a webcast replay will be
available on Hansen Medical's website, and an audio replay will
also be available by calling 877-870-5176 (858-384-5517 for
international callers) and entering the access code 4532840. The
audio replay will be available through May 9, 2012.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, develops products and
technology using robotics for the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The Company's Sensei® X Robotic Catheter System and
Artisan Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in electrophysiology (EP) procedures. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the United
States, the Sensei System is not approved for use in guiding
ablation procedures; this use remains experimental and is currently
under investigation in a multi-center IDE study. The U.S. product
labeling provides that the safety and effectiveness of the Sensei X
System and Artisan Control Catheter for use with cardiac ablation
catheters in the treatment of cardiac arrhythmias, including atrial
fibrillation (AF), have not been established. In the European
Union, the Sensei X System and Artisan Control Catheter are cleared
for use during EP procedures, such as guiding catheters in the
treatment of AF, and the Lynx® Robotic Ablation Catheter is cleared
for the treatment of AF. The Company's Magellan™ Robotic System,
NorthStar™ Robotic Catheter and related accessories, which are
intended to facilitate navigation to anatomical targets in the
peripheral vasculature and subsequently provide a conduit for
manual placement of therapeutic devices, have undergone conformity
assessment and CE marking and are commercially available in the
European Union.
In the U.S., the Magellan™ Robotic System, the NorthStar™
Robotic Catheter and accessories are the subject of a current
filing with the FDA and are not commercially available. Additional
information can be found at www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, expectations,
objectives, milestones and future events. All statements, other
than statements of historical fact, are statements that could be
deemed forward-looking statements, including statements containing
the words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the anticipated growth of Hansen's flexible robotic technology in
both EP and vascular applications and statements about the
anticipated timing of regulatory clearances, including 510(k)
clearance in the United States. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory and sales challenges in developing new products and
entering new markets; potential safety and regulatory issues that
could slow or suspend our sales; the uncertain timelines, costs and
results of pre-clinical and clinical trials; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to maintain our remedial
actions over previously reported material weaknesses in internal
controls over financial reporting; the effect of credit, financial
and economic conditions on capital spending by our potential
customers; our ability to manage expenses and obtain additional
financing; and other risks more fully described in the "Risk
Factors" section of our Annual Report on Form 10-K for the year
ended December 31, 2011 filed with the SEC on March 15, 2012 and
the risks discussed in our other reports filed with the SEC. Given
these uncertainties, you should not place undue reliance on the
forward-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), and Sensei are registered trademarks of Hansen Medical,
Inc. in the United States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Sharrifah Al-Salem, CFA 415.293.4414 Email Contact John
Capodanno 212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024